F-star Therapeutics, Inc.
FSTX · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $3 | $17 |
| % Growth | – | -100% | -85.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $0 | $3 | $17 |
| % Margin | 100% | – | 100% | 100% |
| R&D Expenses | $10 | $9 | $8 | $8 |
| G&A Expenses | $5 | $7 | $6 | $5 |
| SG&A Expenses | $5 | $7 | $6 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $15 | $16 | $14 | $13 |
| Operating Income | -$14 | -$16 | -$11 | $4 |
| % Margin | -1,218.3% | – | -438.6% | 23.9% |
| Other Income/Exp. Net | -$5 | -$3 | -$1 | $0 |
| Pre-Tax Income | -$18 | -$19 | -$12 | $4 |
| Tax Expense | $0 | $0 | $0 | -$1 |
| Net Income | -$18 | -$19 | -$12 | $5 |
| % Margin | -1,641.5% | – | -476.1% | 27.1% |
| EPS | -0.84 | -0.89 | -0.58 | 0.23 |
| % Growth | 5.6% | -53.4% | -352.2% | – |
| EPS Diluted | -0.84 | -0.89 | -0.58 | 0.23 |
| Weighted Avg Shares Out | 22 | 22 | 21 | 21 |
| Weighted Avg Shares Out Dil | 22 | 22 | 21 | 21 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | -$1 |
| Depreciation & Amortization | -$4 | -$2 | -$0 | -$1 |
| EBITDA | -$18 | -$18 | -$12 | $4 |
| % Margin | -1,580.4% | – | -452.1% | 20.4% |